Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.46 USD
Change Today -0.13 / -0.78%
Volume 400.4K
THRX On Other Exchanges
Symbol
Exchange
Munich
NASDAQ GS
As of 4:30 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

theravance inc (THRX) Snapshot

Open
$16.61
Previous Close
$16.59
Day High
$16.82
Day Low
$16.21
52 Week High
07/3/14 - $31.80
52 Week Low
02/2/15 - $10.58
Market Cap
1.9B
Average Volume 10 Days
1.0M
EPS TTM
$-1.13
Shares Outstanding
116.7M
EX-Date
03/10/15
P/E TM
--
Dividend
$1.00
Dividend Yield
4.56%
Current Stock Chart for THERAVANCE INC (THRX)

theravance inc (THRX) Related Businessweek News

View More BusinessWeek News

theravance inc (THRX) Details

Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK). The company is also entitled to a 15% interest in future payments made by GSK relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California.

10 Employees
Last Reported Date: 02/27/15
Founded in 1996

theravance inc (THRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $557.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $87.8K
Senior Vice President of Corporate Partnershi...
Total Annual Compensation: $219.2K
Senior Vice President of Corporate Partnershi...
Total Annual Compensation: $192.9K
Compensation as of Fiscal Year 2014.

theravance inc (THRX) Key Developments

GSK and Theravance Announce Outcome of US FDA Advisory Committee on BREO ELLIPTA in Asthma

GlaxoSmithKline plc and Theravance Inc. announced the outcome of the joint meeting of the Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the United States (US) Food and Drug Administration (FDA) regarding the supplemental New Drug Application (sNDA) for BREO ELLIPTA (fluticasone furoate/vilanterol [FF/VI]) as a once-daily inhaled treatment for asthma in patients aged 12 years and older. The FDA Advisory Committee voted that the efficacy and safety data for FF/VI 100/25 mcg and 200/25 mcg once daily in asthma support approval in adults 18 years of age and older (16 for, 4 against). The Committee voted that the efficacy data provides substantial evidence of a clinically meaningful benefit in adults (18 for, 2 against) and that the safety in this population has been adequately demonstrated (17 for, 3 against). The Committee voted against approval for the proposed indication in 12-17 year olds (2 for, 18 against). The Committee voted that the efficacy data was not sufficient to demonstrate the benefit (4 for, 16 against) and the safety (1 for, 19 against) has not been adequately demonstrated in this sub-population. The Committee recommended that a large LABA safety trial with FF/VI should be required in adults (13 yes, 7 no) and in 12-17 year olds (17 yes, 2 no and 1 no-vote), similar to the ongoing LABA safety trials being conducted as an FDA Post-Marketing Requirement by each of the manufacturers of LABA containing asthma treatments.

Theravance, Inc. Announces Cash Dividend, Payable on March 31, 2015

Theravance Inc. announced that the company's Board of Directors has declared a $0.25 per share cash dividend to be paid on March 31, 2015 to stockholders of record as of the close of business on March 12, 2015.

Theravance Inc. Announces Consolidated Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014

Theravance Inc. announced consolidated unaudited financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, total net revenue was $7,280,000 against $1,473,000 a year ago. Income from operations were $130,000 against loss from operations of $7,417,000 a year ago. Loss from continuing operations, net of tax was $15,926,000 or $0.14 basic and diluted per share against $8,894,000 or $0.08 basic and diluted per share a year ago. Net loss was $15,926,000 against $49,929,000 a year ago. Basic and diluted net loss per common share was $0.14 against $0.46 a year ago. Total revenue which primarily resulted from royalties of $10.5 million from net sales of RELVAR(r)/BREO(r) ELLIPTA(r) and ANORO(r) ELLIPTA(r), offset by amortization of intangible assets of approximately $3.5 million. The majority of the royalties for the fourth quarter were driven by BREO sales, which grew 142% versus the third quarter. This was mainly due to growth in the U.S. and in Japan, associated with the ending of the Ryotan restrictions. For the full year, total net revenue was $8,433,000 against $4,532,000 a year ago. Loss from operations were $33,929,000 against $28,795,000 a year ago. Loss from continuing operations, net of tax was $73,530,000 or $0.66 basic and diluted per share against $30,633,000 or $0.30 basic and diluted per share a year ago. Net loss was $168,464,000 against $170,701,000 a year ago. Basic and diluted net loss per common share was $1.50 against $1.67 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THRX:US $16.46 USD -0.13

THRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ironwood Pharmaceuticals Inc $15.67 USD +0.23
Nektar Therapeutics $11.09 USD +0.18
Progenics Pharmaceuticals Inc $5.79 USD +0.08
Sucampo Pharmaceuticals Inc $14.50 USD +0.50
Synergy Health PLC 2,272 GBp +1.00
View Industry Companies
 

Industry Analysis

THRX

Industry Average

Valuation THRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 224.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 115.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERAVANCE INC, please visit www.thrxinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.